The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction

被引:43
作者
Wang, Frederick
Peled, Anne Warren
Chin, Robin
Fowble, Barbara
Alvarado, Michael
Ewing, Cheryl
Esserman, Laura
Foster, Robert
Sbitany, Hani
机构
[1] Univ Calif San Francisco, Dept Surg, Carol Franc Buck Breast Care Ctr, Div Plast & Reconstruct Surg, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
关键词
SKIN-SPARING MASTECTOMY; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; POSTMASTECTOMY RADIATION; AROMATASE INHIBITORS; POSTMENOPAUSAL WOMEN; AMERICAN-COLLEGE; CANCER PATIENTS; RISK-FACTORS; COMPLICATIONS;
D O I
10.1097/PRS.0000000000001866
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Total skin-sparing mastectomy, with preservation of the nipple-areola complex, must account for adjuvant medical and surgical treatments for cancer. The authors assessed risk factors for complications after second-stage tissue expander-implant exchange. Methods: The authors reviewed all institutional total skin-sparing mastectomy cases that had completed tissue expander-implant exchange with at least 3 months of follow-up. They developed multivariate generalized estimating equation models to obtain adjusted relative risks of radiation therapy, type of lymph node dissection, and hormonal therapy in relation to postoperative complications. Results: The authors performed 776 cases in 489 patients, with a median follow-up of 26 months (interquartile range, 10 to 48 months). Radiation therapy was associated with increased wound breakdown risk [relative risk (RR), 3.3; 95 percent CI, 2.0 to 5.7]; infections requiring oral antibiotics (RR, 2.2; 95 percent CI, 1.31 to 3.6), intravenous antibiotics (RR, 6.4; 95 percent CI, 3.9 to 10.7), or procedures (RR, 8.9; 95 percent CI, 4.5 to 17.5); implant exposure (RR, 3.9; 95 percent CI, 1.86 to 8.3); and implant loss (RR, 4.2; 95 percent CI, 2.4 to 7.4). Axillary lymph node dissection was associated with an increased risk of implant loss (RR, 2.0; 95 percent CI, 1.11 to 3.7) relative to sentinel lymph node biopsy. Conclusions: Axillary lymph node dissection increases the risk of implant loss compared with sentinel lymph node biopsy, independent of radiation therapy. Patients who require axillary lymph node dissection may be encouraged to undergo breast conservation or autologous reconstruction when possible. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 46 条
  • [1] A Paradigm Shift in US Breast Reconstruction: Increasing Implant Rates
    Albornoz, Claudia R.
    Bach, Peter B.
    Mehrara, Babak J.
    Disa, Joseph J.
    Pusic, Andrea L.
    McCarthy, Colleen M.
    Cordeiro, Peter G.
    Matros, Evan
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2013, 131 (01) : 15 - 23
  • [2] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
    Amir, Eitan
    Seruga, Bostjan
    Niraula, Saroj
    Carlsson, Lindsay
    Ocana, Alberto
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17): : 1299 - 1309
  • [3] I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
    Barker, A. D.
    Sigman, C. C.
    Kelloff, G. J.
    Hylton, N. M.
    Berry, D. A.
    Esserman, L. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) : 97 - 100
  • [4] Failure Rate and Cosmesis of Immediate Tissue Expander/Implant Breast Reconstruction After Postmastectomy Irradiation
    Baschnagel, Andrew M.
    Shah, Chirag
    Ben Wilkinson, J.
    Dekhne, Nayana
    Arthur, Douglas W.
    Vicini, Frank A.
    [J]. CLINICAL BREAST CANCER, 2012, 12 (06) : 428 - 432
  • [5] Postmastectomy lymphedema - Long-term results following microsurgical lymph node transplantation
    Becker, C
    Assouad, J
    Riquet, M
    Hidden, G
    [J]. ANNALS OF SURGERY, 2006, 243 (03) : 313 - 315
  • [6] Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
    Boughey, Judy C.
    McCall, Linda M.
    Ballman, Karla V.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Leitch, A. Marilyn
    Flippo-Morton, Teresa
    Hunt, Kelly K.
    [J]. ANNALS OF SURGERY, 2014, 260 (04) : 608 - 616
  • [7] Risk Factors Associated with Breast Lymphedema
    Boughey, Judy C.
    Hoskin, Tanya L.
    Cheville, Andrea L.
    Miller, Joyce
    Loprinzi, Margie D.
    Thomsen, Kristine M.
    Maloney, Shaun
    Baddour, Larry M.
    Degnim, Amy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (04) : 1202 - 1208
  • [8] Carnevale A, 2013, RADIOL MED, V118, P1240, DOI 10.1007/s11547-013-0947-6
  • [9] A Prospective Analysis of 100 Consecutive Lymphovenous Bypass Cases for Treatment of Extremity Lymphedema
    Chang, David W.
    Suami, Hiroo
    Skoracki, Roman
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2013, 132 (05) : 1305 - 1314
  • [10] The role of aromatase inhibitors in early breast cancer
    Cathie T. Chung
    Robert W. Carlson
    [J]. Current Treatment Options in Oncology, 2003, 4 (2) : 133 - 140